Drugs / Hib-MenC-TT
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00135564 | Jan → Jul 2003 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00135486 | Mar 2002 → Jan 2003 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00263653 | Mar 2005 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00258700 | Feb 2005 → Jul 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hib-MenC-TT | “In the booster stage, 476 participants (190 in the UK and 286 in Poland) were vaccinated with Hib-MenC-TT and MMR.” PMID 18463125 ↗ May 20083“Hib-MenC-TT and Priorix™, when given separately, serve as active controls.” NCT00263653 ↗ |
| Modality | Vaccine | “Hib-MenC-TT (Haemophilus influenzae type b-MenC-TT) vaccine” NCT00135486 ↗ |